Each year, Nature Biotechnology highlights companies that have received sizeable early-stage funding in the previous year. Atomic AI generates the structure data it needs for its AI model with the aim of RNA drug discovery.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Townshend, R. J. L. et al. Science 373, 1047–1051 (2021).
Boyd, N. et al. Preprint at bioRxiv https://doi.org/10.1101/2023.12.13.571579 (2023).
National Academies of Sciences, Engineering, and Medicine. Charting a Future for Sequencing RNA and its Modifications: A New Era for Biology and Medicine (National Academies Press, 2024); https://doi.org/10.17226/27165
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Marx, V. Editor’s pick: Atomic AI. Nat Biotechnol 42, 1341–1342 (2024). https://doi.org/10.1038/s41587-024-02375-0
Published:
Issue date:
DOI: https://doi.org/10.1038/s41587-024-02375-0
